Clinical Trial for HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Now enrolling: Window-of-opportunity trial of neoadjuvant ADXS11-001 vaccination prior to robot-assisted resection of HPV-positive oropharyngeal squamous cell carcinoma
Patients diagnosed with HPV-related oropharyngeal (throat) cancer who are eligible to undergo robot-assisted surgery may be eligible for a therapeutic clinical trial testing a novel vaccine (ADXS11-001). Under the direction of co-principal investigators Brett Miles, DDS, MD, and Marshall Posner, MD, this trial is currently enrolling new participants.
You may be eligible if:
- You have Biopsy-proven squamous cell carcinoma of the oropharynx (tonsil or base of tongue)
- Your tumor is HPV positive
- Your cancer is in clinical stages I-IV
- You qualify for surgical resection by transoral robot-assisted surgery (TORS)
You will not be eligible if:
- You have a history of cancer of the head and neck (except skin cancer)
- You are a recent (less than 3 years) survivor of cancer in any other location (except skin cancer)
- You have a history of cancer therapy with chemotherapy and/or radiation
- You are immunosuppressed or use immunosuppressive medications (HIV, transplant recipients, chronic steroids users, etc.)
- Other medical exclusion criteria may apply
This trial includes a vaccine that uses a novel principal to stimulate the immune system, inducing a strong immune response in the patient. Unlike preventive vaccines, this is a therapeutic approach for patients who already have HPV-related oral cancer. Patients who receive the vaccine will undergo surgery and receive post-surgical treatment in addition to the vaccine.
To inquire about this trial, please contact us at:
For more information:
Learn more details about this clinical trial, such as inclusion and exclusion criteria. Read more
Mount Sinai's Head and Neck Cancer Program is pleased to offer this therapeutic vaccine trial for patients with HPV-related oropharyngeal cancer.